Investment
Features
FeesSafety
Academy
More
Pluang+

NewLake Capital Partners downgraded to buy due to risks despite attractive valuation in cannabis real estate.

Analyst Insights
17 Sep 2026
Seeking Alpha
View Source
Neutral
NewLake Capital Partners downgraded to buy due to risks despite attractive valuation in cannabis real estate.

NewLake Capital Partners (NLCP) has been downgraded to a buy rating because its risk-to-reward ratio is less attractive, even though its valuation remains appealing. The company operates in the niche cannabis real estate market, which holds strong growth potential if legal changes occur at state and federal levels. However, risks include high tenant concentration, with over half of NLCP's rent coming from its top three tenants, and ongoing uncertainty related to The Cannabist bankruptcy. NLCP trades at a low forward price-to-funds-from-operations (P/FFO) ratio of 8.0x, but investors should closely watch legal developments, tenant stability, and progress on filling vacant properties.

NewLake Capital Partners and its recent downgrade are presented here with Pluang's Real Estate sector data as of Sep 17, 2026 23:42 WIB. For readers following Real Estate, 20 of 22 priced US stocks rose today. Notable movers include CCI at USD 73.90 with a 0.93% increase and 100% buy order activity, ESS at USD 273.46 up 0.76%, and OPEN at USD 2.60 rising 0.58% despite 82% sell order activity.

More News

Jefferies keeps Kinder Morgan on Hold, lowers price target to $33 amid stable cash flows and growth.

Jefferies keeps Kinder Morgan on Hold, lowers price target to $33 amid stable cash flows and growth.

Jefferies maintained a Hold rating on Kinder Morgan, lowering its price target from $35 to $33, which remains above the current stock price of $31.31. The company benefits from stable cash flows, with 96% secured by fee-based or hedged contracts, inc...

Analyst Insights
Neutral
24 minutes ago
Stocks surge on patent wins, financing deals, and merger announcements.

Stocks surge on patent wins, financing deals, and merger announcements.

Several stocks saw sharp gains driven by key company developments. bioAffinity Technologies surged 63.55% after securing a Hong Kong patent for its lung cancer diagnostic technology, boosting its Asian market position. Antelope Enterprise Holdings ro...

Market News
Bullish
33 minutes ago
KB Home Q3 earnings expected to drop sharply, with revenue and EPS forecast down significantly.

KB Home Q3 earnings expected to drop sharply, with revenue and EPS forecast down significantly.

KB Home is set to report its Q3 2026 earnings on September 22, with analysts projecting a 45.3% drop in earnings per share to around $0.89 and a 20.2% decline in revenue to about $1.30 billion compared to last year. The consensus EPS estimate has rec...

Company Fundamentals
Bearish
1 hour ago
$10,000 invested in Nebius in 2024 is now worth about $105,000 in 2026

$10,000 invested in Nebius in 2024 is now worth about $105,000 in 2026

An investment of $10,000 in Nebius when it resumed trading in 2024 has grown significantly to approximately $105,000 by 2026. This remarkable increase highlights Nebius's strong market performance over the two-year period. Investors who bought in at ...

Market News
Bullish
3 hours ago
W.P. Carey projects $1.9B investment in 2026 with strong tenant outlook and institutional support.

W.P. Carey projects $1.9B investment in 2026 with strong tenant outlook and institutional support.

W.P. Carey expects to invest over $1.9 billion in 2026, reflecting robust growth in its net lease property portfolio. Despite a slight reduction in its price target by Scotiabank to $76, the stock still shows potential upside from current levels. The...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App